Table 2.

Results for base-case and scenario analyses in the cost-effectiveness analysis of TDM-guided adjuvant tamoxifen dosing versus the standard care (without TDM)

	Total costs	Total LYs	Total QALYs	Incremental costs	Incremental LYs	Incremental QALYs	ICER (costs QALY gained)
Base case
TDM	€32,893	19.84	16.51	− €6631	0.40	0.53	TDM dominates
SC	€39,524	19.45	15.98
S1a. 100% on threshold (20% benefits)
TDM	€26,369	20.41	17.01	− €13,155	0.96	1.03	TDM dominates
SC	€39,524	19.45	15.98
S1b. 95% on threshold (15% benefits)
TDM	€28,975	20.01	16.67	− €10,549	0.57	0.69	TDM dominates
SC	€39,524	19.45	15.98
S1c. 85% on threshold (5% benefits)
TDM	€41,076	20.09	16.69	€1552	0.64	0.71	€2177
SC	€39,524	19.45	15.98
S1d. Correction factor recurrence rate assumption
TDM	€26,573	20.10	16.76	− €12,951	0.65	0.76	TDM dominates
SC	€39,524	19.45	16.00
S2a. RD high
TDM	€37,786	19.84	16.53	− €7966	0.40	0.53	TDM dominates
SC	€45,752	19.45	16.00
S2b. RD low
TDM	€14,359	19.84	16.53	− €1573	0.40	0.53	TDM dominates
SC	€15,932	19.45	16.00
S3. Productivity loss
TDM	€70,531	19.84	16.53	− €9549	0.40	0.53	TDM dominates
SC	€80,080	19.45	16.00
S4a. Alternative curve fit: loglogistic
TDM	€34,716	17.36	20.83	− €7511	0.34	0.49	TDM dominates
SC	€42,227	16.86	20.49
S4b. Alternative curve fit: lognormal
TDM	€34,997	17.96	21.56	− €7429	0.34	0.50	TDM dominates
SC	€42,426	17.47	21.22
S4c. Alternative curve fit: exponential
TDM	€21,917	18.14	21.72	− €12,397	0.34	0.52	TDM dominates
SC	€34,314	17.62	21.38

ICER incremental cost-effectiveness ratio, LYs life years, QALYs quality-adjusted life years, S scenario, SC tamoxifen standard care (without TDM intervention), TDM therapeutic drug monitoring-guided tamoxifen dosing